|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Bayer AG (BAY) Completes Transaction Involving Plasma Business; Announcing The Launch Of Talecris Biotherapeutics, Holdings Corp.: Combining A Proud History Of Patient Care With A Bold New Vision
10/19/2005 5:13:11 PM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--April 1, 2005--
Talecris To Apply Innovative Approach to Its Inherited, 60-Year Legacy of Providing Life-Saving and Life Enhancing Plasma-Derived Therapeutic Proteins
Talecris Biotherapeutics, Holdings Corp. (Talecris), a new corporation that acquired the contributed assets of Bayer HealthCare, LLC, Biological Products Division's (BP) plasma business, today launches its worldwide therapeutic proteins business, Talecris Biotherapeutics, Inc.
The transaction between Bayer and Talecris was completed yesterday, with the new company becoming operational today. Private investment firms Cerberus Capital Management, L.P., New York, and Ampersand Ventures of Wellesley, Mass., provided the financial backing for Talecris.
|
|
|
|
|
|
|
|
|
|
|